About NeuroBo Pharmaceuaticals
NeuroBo Pharmaceuticals is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. Their first product candidate, NB-01, is targeting neuropathic pain with a first indication in PDN. Phase 3 studies are planned and powered for efficacy and safety.
Diabetes and cancer are amongst the leading causes of neuropathic pain. PDN affects 8.4M people worldwide representing global drug sales of $3.05B (2018, GlobalData) Current treatments show limited reduction of pain in half of patients
State of Ownership